EXHIBIT 99.1 Addex Reports Full Year 2021 Financial Results and Provides Corporate Update CHF20.5M ($22.5M) of cash and cash equivalents at December 31, 2021 Dipraglurant Phase 2 blepharospasm clinical trial on track to report data in Q2 2022 Phase 2b/3 dipraglurant study in dyskinesia associated with Parkinson's disease expected to report data in H1 2023 Janssen led ADX71149 Phase 2 study in epilepsy on track to report data in Q3 2022 Indivior GABAB PAM strategic collaboration extended with $4M additional ...

Addex Therapeutics Limited (NASDAQ:ADXN) Q4 2020 Earnings Conference Call March 11, 2021 10:00 AM ET Company Participants Tim Dyer - CEO Roger Mills - Chief Medical Officer Robert Lutjens - Head of Discovery Biology Conference Call Participants Operator Ladies and gentlemen, welcome to the Webex Conference of Addex Therapeutics regarding the announcement of the Full Year 2020 Financial Results. At our customer's request this conference will be recorded. As a reminder, all participants will be in a listen-o ...

Use these links to rapidly review the document TABLE OF CONTENTS INDEX TO FINANCIAL STATEMENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EX ...